Antithrombotic therapy supplement. - NGC AHRQ

Institute for Clinical Systems Improvement
1. Antithrombotic therapy supplement. This updates a previously published guideline summary.
GUIDELINE TITLE
Antithrombotic therapy supplement.

BIBLIOGRAPHIC SOURCE(S)
Institute for Clinical Systems Improvement (ICSI). Antithrombotic therapy supplement. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2009 Apr. 69 p. [138 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Antithrombotic therapy supplement. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Aug. 64 p.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

November 17, 2009 - Plavix (clopidogrel): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of new safety information concerning an interaction between clopidogrel (Plavix) and omeprazole (Prilosec/Prilosec OTC) used to reduce stomach acid. New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced.

abrir aquí:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=14855&nbr=&string=